Surv BioPharma Inc.


Development Pipeline

Oncolytic viruses (OVs)

  • Using the promoter for expression of survivin, a highly cancer cell-specific protein, we have successfully developed a pipeline of OVs (the Surv.m-CRA series) that only attack cancer cells without attacking normal cells.
  • In addition to Surv.m-CRA-1 currently in clinical development for the treatment of malignant bone tumors, we are also developing the Type 2 OV drug candidates “Surv.m-CRA-2-G” and “Surv.m-CRA-2-IC” armed with therapeutic genes that stimulate autoimmunity.

Viruses for in vivo gene therapy

  • We have developed a pipeline of several therapeutic viruses armed with genes such as those encoding hepatocyte growth factor (HGF), which is effective in the treatment of hepatic disease and diabetes mellitus.
  • We have confirmed the effects of these viral vectors in repairing liver damage and controlling blood glucose in nonclinical mouse models.